Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
about
Memantine inhibits α3β2-nAChRs-mediated nitrergic neurogenic vasodilation in porcine basilar arteriesAcetyl-CoA the key factor for survival or death of cholinergic neurons in course of neurodegenerative diseasesNeurotransmitter receptors in the life and death of oligodendrocytesSpecific and disease stage-dependent episodic memory-related brain activation patterns in Alzheimer’s disease: a coordinate-based meta-analysisAmyloid-β and Astrocytes Interplay in Amyloid-β Related DisordersN-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseaseGlutamatergic autoencephalitides: an emerging fieldNeuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseCurrent approaches to enhance glutamate transporter function and expressionTrafficking of excitatory amino acid transporter 2-laden vesicles in cultured astrocytes: a comparison between approximate and exact determination of trajectory angles.Mechanisms of Modal Activation of GluA3 ReceptorsThe Structure of (-)-Kaitocephalin Bound to the Ligand Binding Domain of the (S)- -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA)/Glutamate Receptor, GluA2The Loss of an Electrostatic Contact Unique to AMPA Receptor Ligand Binding Domain 2 Slows Channel ActivationRole of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute NeuropathologiesProtection against beta-amyloid-induced apoptosis by peptides interacting with beta-amyloidAmyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2Amyloid-precursor-protein-lowering small molecules for disease modifying therapy of Alzheimer's diseaseCombinations of Ashwagandha leaf extracts protect brain-derived cells against oxidative stress and induce differentiationGenome-wide association scan of trait depressionThe alphabet of intrinsic disorder: II. Various roles of glutamic acid in ordered and intrinsically disordered proteins.Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding Aβ plaques by iGluSnFR two-photon imaging.The Chemistry of Neurodegeneration: Kinetic Data and Their Implications.Functional expression, purification and high sequence coverage mass spectrometric characterization of human excitatory amino acid transporter EAAT2The role of glutamate in anxiety and related disorders.Novel dimeric acetylcholinesterase inhibitor bis7-tacrine, but not donepezil, prevents glutamate-induced neuronal apoptosis by blocking N-methyl-D-aspartate receptors.Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's diseaseMedial septal beta-amyloid 1-40 injections alter septo-hippocampal anatomy and function.Prolactin-induced neuroprotection against glutamate excitotoxicity is mediated by the reduction of [Ca2+]i overload and NF-κB activation.Wallerian-like axonal degeneration in the optic nerve after excitotoxic retinal insult: an ultrastructural study.Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases.Methamphetamine-induced cell death: selective vulnerability in neuronal subpopulations of the striatum in miceDrug candidates in clinical trials for Alzheimer's disease.Pathologically activated neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by novel multifunctional dimer bis(propyl)-cognitin.Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline.Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects.Intersection between metabolic dysfunction, high fat diet consumption, and brain aging.Metal chaperones: a holistic approach to the treatment of Alzheimer's diseaseNeuroprotection by acetoacetate and β-hydroxybutyrate against NMDA-induced RGC damage in rat--possible involvement of kynurenic acidNeuroprotective effects of huperzine A. A natural cholinesterase inhibitor for the treatment of Alzheimer's disease.
P2860
Q21134148-63DA8D8C-CD94-4271-84F2-59F604189438Q24608842-D8A02832-FED8-41D9-9EA9-DD424F97B9A1Q24671657-87AF939B-FC29-420C-9FF6-42BF16AD0A60Q24758018-04D993DB-B529-474C-8D1A-AC42DC3CACE8Q26766934-435A50BA-A943-4D09-AFF6-32E4E6AF3ABDQ26825619-D46659FD-3F31-4559-AF76-44B610372885Q26992294-98FD3BE8-D522-4EA5-988B-F8BE95A74C2EQ26995351-0C90FD95-8997-4D92-96B5-75005EDF8E1DQ26996723-DB5D077E-FCD0-4853-87C0-9D98B3290C56Q27319915-589D3014-82AA-47EB-B158-9077C7ACAC04Q27667420-9C08D347-5182-45B7-8870-480B0B55598CQ27674617-B810E683-1AB3-4E13-9ABA-688704EC3778Q27678596-5DE39E83-66C2-4779-B8D0-43DE22572F34Q28072353-789B8D54-DDD3-470A-9EC7-2975290FE76FQ28244030-82137B9B-3F6A-4508-AF00-41612A94795FQ28482267-D64C1330-2823-499F-BBD9-AC63A8C0181FQ28537717-EBDF9ABA-865F-4F34-8A27-DB90799B541AQ28544672-6BC1A435-5CFC-4567-88CE-BF2113214D99Q28943415-88A500B1-9216-4E89-9569-42AA4BEEB303Q30402098-E772EA4C-5518-4CA8-BBC8-766BC786BE3CQ30416730-208CE79A-7F67-4363-8030-D039F77044FFQ30829062-69F69E53-0000-4E90-A59A-A5400604EA71Q30973484-1F063992-961D-48EC-BFF4-EFD7C41053D0Q30981324-CE61B632-9B1D-46E2-A96A-D367723AABE9Q31029023-EF444061-9986-468B-999E-1FA3393A2CD8Q33211908-80F76FA6-8779-454C-8EFF-89C28A40EA53Q33494148-9BC483C0-1A1F-4CF1-B231-6167A0E53C20Q33605897-7BDE4E56-4D01-497E-98F6-B6124E8D359FQ33643044-43F6B37A-C827-451A-AC83-5295D9C28474Q33657315-CEC35927-A9EA-4F20-A608-49A7B5AF0DD8Q33891870-C166D7C4-2FCB-4B86-8D74-D4A75EB9C963Q33899756-C6149853-0ED8-45B4-B778-B89C33C2CC76Q33916749-A7226988-E266-4789-A87D-711F704C9BD8Q33924304-5B45D002-0D08-4319-9B9D-EAD074DA174EQ34002796-8AEC2633-3575-4253-AA16-D852A5B352B2Q34007510-FB97BD1D-56FA-4840-92AC-EE4099314E91Q34020532-BA854FED-5FA7-427E-845E-25C46B99FBB3Q34260002-08C9DE92-2906-4AFE-A98E-4220C8D3E4E0Q34280603-808ED573-8BC4-4061-9D64-DFCD7D0E8BE8Q34426624-FEF2D199-8AF6-4048-AC8F-403D0683324E
P2860
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
name
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@ast
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@en
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@nl
type
label
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@ast
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@en
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@nl
prefLabel
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@ast
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@en
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@nl
P2093
P1476
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease.
@en
P2093
Heather L Scott
Matthew R Hynd
Peter R Dodd
P304
P356
10.1016/J.NEUINT.2004.03.007
P577
2004-10-01T00:00:00Z